To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma
Clinical trial NCT04682587 · COMPLETED
Trial details
- NCT number
- NCT04682587
- Sponsor
- Pfizer
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2021-02-24
- Primary completion
- 2021-04-05
- Enrollment
- 481
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.